42-ETHYL-14-FLUORO-83-HYDROXY-3,48-DIMETHYL-7-OXO-3-AZA-4(3,6)-IMIDAZO(1,2-A)PYRIDINA-5(1,4)-PIPERAZINA-2(4,2)-(1,3)THIAZOLA-8(1)-AZETIDINA-1(1)-BENZENAOCTAPHANE-25-CARBONITRILE

Systemic Sclerosis

Lakefront Biotherapeutics NVSmall moleculePhase 2Dormant

CCC

51/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 36/ 100
Competitive Position: 95/ 100

Competitive context

25 Active assets in the Systemic Sclerosis cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Royal Brompton & Harefield NHS Foundation Trust	Phase 2/3	BB
Iloprost National Center for Research Resources (NCRR)	Phase 3	BB
Bosentan Actelion	Phase 3	B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Royal Brompton & Harefield NHS Foundation Trust	Phase 2/3	B
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center	Phase 2	B

View all 41 →

Same molecule, other indications

42-ETHYL-14-FLUORO-83-HYDROXY-3,48-DIMETHYL-7-OXO-3-AZA-4(3,6)-IMIDAZO(1,2-A)PYRIDINA-5(1,4)-PIPERAZINA-2(4,2)-(1,3)THIAZOLA-8(1)-AZETIDINA-1(1)-BENZENAOCTAPHANE-25-CARBONITRILE is also rated in:

idiopathic pulmonary fibrosisDormant

CCC

Indicative ·

52 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →